Cargando…
Machine-Learning-Based Radiomics MRI Model for Survival Prediction of Recurrent Glioblastomas Treated with Bevacizumab
Anti-angiogenic therapy with bevacizumab is a widely used therapeutic option for recurrent glioblastoma (GBM). Nevertheless, the therapeutic response remains highly heterogeneous among GBM patients with discordant outcomes. Recent data have shown that radiomics, an advanced recent imaging analysis m...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305059/ https://www.ncbi.nlm.nih.gov/pubmed/34359346 http://dx.doi.org/10.3390/diagnostics11071263 |
_version_ | 1783727483799994368 |
---|---|
author | Ammari, Samy Sallé de Chou, Raoul Assi, Tarek Touat, Mehdi Chouzenoux, Emilie Quillent, Arnaud Limkin, Elaine Dercle, Laurent Hadchiti, Joya Elhaik, Mickael Moalla, Salma Khettab, Mohamed Balleyguier, Corinne Lassau, Nathalie Dumont, Sarah Smolenschi, Cristina |
author_facet | Ammari, Samy Sallé de Chou, Raoul Assi, Tarek Touat, Mehdi Chouzenoux, Emilie Quillent, Arnaud Limkin, Elaine Dercle, Laurent Hadchiti, Joya Elhaik, Mickael Moalla, Salma Khettab, Mohamed Balleyguier, Corinne Lassau, Nathalie Dumont, Sarah Smolenschi, Cristina |
author_sort | Ammari, Samy |
collection | PubMed |
description | Anti-angiogenic therapy with bevacizumab is a widely used therapeutic option for recurrent glioblastoma (GBM). Nevertheless, the therapeutic response remains highly heterogeneous among GBM patients with discordant outcomes. Recent data have shown that radiomics, an advanced recent imaging analysis method, can help to predict both prognosis and therapy in a multitude of solid tumours. The objective of this study was to identify novel biomarkers, extracted from MRI and clinical data, which could predict overall survival (OS) and progression-free survival (PFS) in GBM patients treated with bevacizumab using machine-learning algorithms. In a cohort of 194 recurrent GBM patients (age range 18–80), radiomics data from pre-treatment T2 FLAIR and gadolinium-injected MRI images along with clinical features were analysed. Binary classification models for OS at 9, 12, and 15 months were evaluated. Our classification models successfully stratified the OS. The AUCs were equal to 0.78, 0.85, and 0.76 on the test sets (0.79, 0.82, and 0.87 on the training sets) for the 9-, 12-, and 15-month endpoints, respectively. Regressions yielded a C-index of 0.64 (0.74) for OS and 0.57 (0.69) for PFS. These results suggest that radiomics could assist in the elaboration of a predictive model for treatment selection in recurrent GBM patients. |
format | Online Article Text |
id | pubmed-8305059 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83050592021-07-25 Machine-Learning-Based Radiomics MRI Model for Survival Prediction of Recurrent Glioblastomas Treated with Bevacizumab Ammari, Samy Sallé de Chou, Raoul Assi, Tarek Touat, Mehdi Chouzenoux, Emilie Quillent, Arnaud Limkin, Elaine Dercle, Laurent Hadchiti, Joya Elhaik, Mickael Moalla, Salma Khettab, Mohamed Balleyguier, Corinne Lassau, Nathalie Dumont, Sarah Smolenschi, Cristina Diagnostics (Basel) Article Anti-angiogenic therapy with bevacizumab is a widely used therapeutic option for recurrent glioblastoma (GBM). Nevertheless, the therapeutic response remains highly heterogeneous among GBM patients with discordant outcomes. Recent data have shown that radiomics, an advanced recent imaging analysis method, can help to predict both prognosis and therapy in a multitude of solid tumours. The objective of this study was to identify novel biomarkers, extracted from MRI and clinical data, which could predict overall survival (OS) and progression-free survival (PFS) in GBM patients treated with bevacizumab using machine-learning algorithms. In a cohort of 194 recurrent GBM patients (age range 18–80), radiomics data from pre-treatment T2 FLAIR and gadolinium-injected MRI images along with clinical features were analysed. Binary classification models for OS at 9, 12, and 15 months were evaluated. Our classification models successfully stratified the OS. The AUCs were equal to 0.78, 0.85, and 0.76 on the test sets (0.79, 0.82, and 0.87 on the training sets) for the 9-, 12-, and 15-month endpoints, respectively. Regressions yielded a C-index of 0.64 (0.74) for OS and 0.57 (0.69) for PFS. These results suggest that radiomics could assist in the elaboration of a predictive model for treatment selection in recurrent GBM patients. MDPI 2021-07-14 /pmc/articles/PMC8305059/ /pubmed/34359346 http://dx.doi.org/10.3390/diagnostics11071263 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ammari, Samy Sallé de Chou, Raoul Assi, Tarek Touat, Mehdi Chouzenoux, Emilie Quillent, Arnaud Limkin, Elaine Dercle, Laurent Hadchiti, Joya Elhaik, Mickael Moalla, Salma Khettab, Mohamed Balleyguier, Corinne Lassau, Nathalie Dumont, Sarah Smolenschi, Cristina Machine-Learning-Based Radiomics MRI Model for Survival Prediction of Recurrent Glioblastomas Treated with Bevacizumab |
title | Machine-Learning-Based Radiomics MRI Model for Survival Prediction of Recurrent Glioblastomas Treated with Bevacizumab |
title_full | Machine-Learning-Based Radiomics MRI Model for Survival Prediction of Recurrent Glioblastomas Treated with Bevacizumab |
title_fullStr | Machine-Learning-Based Radiomics MRI Model for Survival Prediction of Recurrent Glioblastomas Treated with Bevacizumab |
title_full_unstemmed | Machine-Learning-Based Radiomics MRI Model for Survival Prediction of Recurrent Glioblastomas Treated with Bevacizumab |
title_short | Machine-Learning-Based Radiomics MRI Model for Survival Prediction of Recurrent Glioblastomas Treated with Bevacizumab |
title_sort | machine-learning-based radiomics mri model for survival prediction of recurrent glioblastomas treated with bevacizumab |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305059/ https://www.ncbi.nlm.nih.gov/pubmed/34359346 http://dx.doi.org/10.3390/diagnostics11071263 |
work_keys_str_mv | AT ammarisamy machinelearningbasedradiomicsmrimodelforsurvivalpredictionofrecurrentglioblastomastreatedwithbevacizumab AT salledechouraoul machinelearningbasedradiomicsmrimodelforsurvivalpredictionofrecurrentglioblastomastreatedwithbevacizumab AT assitarek machinelearningbasedradiomicsmrimodelforsurvivalpredictionofrecurrentglioblastomastreatedwithbevacizumab AT touatmehdi machinelearningbasedradiomicsmrimodelforsurvivalpredictionofrecurrentglioblastomastreatedwithbevacizumab AT chouzenouxemilie machinelearningbasedradiomicsmrimodelforsurvivalpredictionofrecurrentglioblastomastreatedwithbevacizumab AT quillentarnaud machinelearningbasedradiomicsmrimodelforsurvivalpredictionofrecurrentglioblastomastreatedwithbevacizumab AT limkinelaine machinelearningbasedradiomicsmrimodelforsurvivalpredictionofrecurrentglioblastomastreatedwithbevacizumab AT derclelaurent machinelearningbasedradiomicsmrimodelforsurvivalpredictionofrecurrentglioblastomastreatedwithbevacizumab AT hadchitijoya machinelearningbasedradiomicsmrimodelforsurvivalpredictionofrecurrentglioblastomastreatedwithbevacizumab AT elhaikmickael machinelearningbasedradiomicsmrimodelforsurvivalpredictionofrecurrentglioblastomastreatedwithbevacizumab AT moallasalma machinelearningbasedradiomicsmrimodelforsurvivalpredictionofrecurrentglioblastomastreatedwithbevacizumab AT khettabmohamed machinelearningbasedradiomicsmrimodelforsurvivalpredictionofrecurrentglioblastomastreatedwithbevacizumab AT balleyguiercorinne machinelearningbasedradiomicsmrimodelforsurvivalpredictionofrecurrentglioblastomastreatedwithbevacizumab AT lassaunathalie machinelearningbasedradiomicsmrimodelforsurvivalpredictionofrecurrentglioblastomastreatedwithbevacizumab AT dumontsarah machinelearningbasedradiomicsmrimodelforsurvivalpredictionofrecurrentglioblastomastreatedwithbevacizumab AT smolenschicristina machinelearningbasedradiomicsmrimodelforsurvivalpredictionofrecurrentglioblastomastreatedwithbevacizumab |